AIC
ESPR

Ameritas Investment Company’s Esperion Therapeutics ESPR Stock Holding History

Ameritas Investment Company’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-100
Closed -$5K – 1224
2018
Q4 		$5K Buy
+100
New +$4.82K ﹤0.01% 1212

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Ameritas Investment Company's ESPR Position: Q1 2019 in Review

Ameritas Investment Company sold out of Esperion Therapeutics (ESPR) in Q1 2019, closing a stake of 100 shares — an estimated $5K sold.

Ameritas Investment Company first reported a position in ESPR in Q4 2018 and held it in 1 quarter. The position peaked at $5K in Q4 2018. 163 funds tracked by Wall St. Rank hold ESPR as of Q1 2019.

  • Ameritas Investment Company reported no remaining Esperion Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Ameritas Investment Company sold 100 Esperion Therapeutics shares in Q1 2019, an estimated $5K.
  • Ameritas Investment Company first reported a position in Esperion Therapeutics in Q4 2018 and held it in 1 quarter.
  • Ameritas Investment Company's Esperion Therapeutics position peaked at $5K in Q4 2018.
  • 163 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2019.

Based on Ameritas Investment Company's 13F filing for Q1 2019, filed 16 May 2019.